Mixed investment funds also see demand
Simplifying financial products for consumers
Highlights other challenges for the year
Inflation pressures realised
Revamp of FS Register on cards
2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and BB Biotech's holdings in focus. The investment team expects new product launches...
Latest edition of the print magazine online